High-Dose-Rate Interstitial Brachytherapy (Interventional Radiotherapy) for Conjunctival Melanoma with Orbital Extension.
Brachytherapy
Conjunctival melanoma
Ocular oncology
Ocular tumors
Ophthalmic oncology
Journal
Ocular oncology and pathology
ISSN: 2296-4681
Titre abrégé: Ocul Oncol Pathol
Pays: Switzerland
ID NLM: 101656139
Informations de publication
Date de publication:
Jun 2021
Jun 2021
Historique:
received:
28
07
2020
accepted:
15
10
2020
entrez:
26
7
2021
pubmed:
27
7
2021
medline:
27
7
2021
Statut:
ppublish
Résumé
To evaluate local control and functional and cosmetic outcomes of postoperative high-dose-rate interventional radiotherapy (HDR-IRT) in patients affected by conjunctival melanoma with orbit invasion. A retrospective study was conducted in 2 patients affected by conjunctival melanoma infiltrating the orbit, treated with surgical excision and HDR-IRT. The treatment procedures consisted of surgical excision of the orbital infiltrating nodule followed, 1 month after surgery, by adjuvant HDR-IRT. A target dose of 34 Gy was delivered in 10 twice-a-day fractions over 5 consecutive days. Data analysis included local tumor control and metastatic rate, acute and late toxicity, functional and aesthetic results. In both patients, treatment was well tolerated, and there was no orbital recurrence at a median follow-up of 37-40 months. There was an excellent functional outcome, without no significant acute or late side effects. HDR-IRT could be considered a promising, feasible, successful, and well-tolerated option for selected patients affected by ocular tumors with orbital invasion.
Identifiants
pubmed: 34307333
doi: 10.1159/000512344
pii: oop-0007-0199
pmc: PMC8280431
doi:
Types de publication
Case Reports
Langues
eng
Pagination
199-205Informations de copyright
Copyright © 2021 by S. Karger AG, Basel.
Déclaration de conflit d'intérêts
The authors have no conflicts of interest to declare.
Références
Br J Ophthalmol. 1994 Jul;78(7):520-8
pubmed: 7522545
Semin Radiat Oncol. 2002 Jan;12(1):95-108
pubmed: 11813154
Br J Ophthalmol. 1993 Oct;77(10):624-30
pubmed: 8218029
Indian J Ophthalmol. 2019 Dec;67(12):2071-2073
pubmed: 31755463
Arch Ophthalmol. 1984 Nov;102(11):1606-11
pubmed: 6497741
Radiat Oncol. 2019 Dec 27;14(1):239
pubmed: 31881977
Ophthalmic Plast Reconstr Surg. 1997 Mar;13(1):31-5
pubmed: 9076781
Tumori. 2017 Nov 23;103(6):516-524
pubmed: 28291904
Expert Rev Ophthalmol. 2014 Jun;9(3):185-204
pubmed: 25580155
Eye (Lond). 2013 Feb;27(2):142-52
pubmed: 23222568
Br J Ophthalmol. 2006 Nov;90(11):1438-9
pubmed: 17057181
Ophthalmic Plast Reconstr Surg. 2008 Nov-Dec;24(6):444-9
pubmed: 19033839
Ocul Oncol Pathol. 2018 Jun;4(4):261-266
pubmed: 30643772
Invest Ophthalmol Vis Sci. 2005 Jan;46(1):75-82
pubmed: 15623757
Surv Ophthalmol. 2009 Sep-Oct;54(5):545-68
pubmed: 19682622
Ophthalmologica. 2008;222(5):338-43
pubmed: 18635931
Br J Ophthalmol. 2005 Oct;89(10):1335-40
pubmed: 16170127
J Contemp Brachytherapy. 2017 Oct;9(5):466-471
pubmed: 29204167
Graefes Arch Clin Exp Ophthalmol. 1996 Sep;234(9):569-72
pubmed: 8880155
Ophthalmic Plast Reconstr Surg. 2003 Mar;19(2):91-5
pubmed: 12644752
Front Radiat Ther Oncol. 1997;30:56-64
pubmed: 9205885
J Contemp Brachytherapy. 2015 Jan;6(4):404-16
pubmed: 25834586
Ophthalmic Plast Reconstr Surg. 1995 Sep;11(3):169-81
pubmed: 8541258
Ophthalmology. 2000 May;107(5):951-8
pubmed: 10811089
Graefes Arch Clin Exp Ophthalmol. 2006 Apr;244(4):438-46
pubmed: 16133022
JAMA Ophthalmol. 2018 Nov 1;136(11):1236-1241
pubmed: 30352118
Brachytherapy. 2015 May-Jun;14(3):419-25
pubmed: 25620162
Pathol Oncol Res. 2018 Oct;24(4):787-796
pubmed: 29802540
Strahlenther Onkol. 2011 May;187(5):322-7
pubmed: 21533761
Front Oncol. 2017 Jun 23;7:125
pubmed: 28690979
Klin Monbl Augenheilkd. 2002 Oct;219(10):710-21
pubmed: 12447715
Ophthalmic Epidemiol. 2006 Apr;13(2):85-96
pubmed: 16581612
Graefes Arch Clin Exp Ophthalmol. 2019 Jun;257(6):1309-1318
pubmed: 30919076
Graefes Arch Clin Exp Ophthalmol. 2019 Aug;257(8):1783-1788
pubmed: 31098751
Brachytherapy. 2014 May-Jun;13(3):275-80
pubmed: 24139892